As a potent inducer of DNA damage in targeted tumor cells, it is anticipated that 225Ac‐lintuzumab may mediate effective down‐modulation of MCL‐1 leading to a sensitization of AML cells to venetoclax irrespective of inherent resistance to the BCL‐2 inhibitor. This evidence concerns the gene BCL2 and acute myeloid leukemia.